Response Pharmaceuticals has completed enrollment ahead of schedule for their Phase 2 trial of RDX-002, a novel iMTP inhibitor designed to prevent weight rebound after GLP-1 agonist discontinuation.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.